Esperion Therapeutics, Inc. (ESPR) — Analyst outlook / Analyst consensus target is. Based on 25 analyst ratings, the consensus is bullish — 10 Buy, 13 Hold, 2 Sell.
The consensus price target is $9.00, representing an upside of 339% from the current price $2.05.
Analysts estimate Earnings Per Share (EPS) of $-0.32 and revenue of $0.33B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.28 vs est $-0.32 (beat +11.9%). 2025: actual $-0.11 vs est $-0.09 (missed -26.2%). Analyst accuracy: 83%.
ESPR Stock — 12-Month Price Forecast
$9.00
▲ +339.02% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Esperion Therapeutics, Inc., the price target is $9.00.
The average price target represents a +339.02% change from the last price of $2.05.
ESPR Analyst Ratings
Hold
Based on 25 analysts giving stock ratings to Esperion Therapeutics, Inc. in the past 3 months
EPS Estimates — ESPR
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.28
vs Est –$0.32
▲ 13.5% off
2025
Actual –$0.11
vs Est –$0.09
▼ 20.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ESPR
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.332B
vs Est $0.325B
▲ 2.3% off
2025
Actual $0.403B
vs Est $0.402B
▲ 0.2% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
